Ranking Profile - AnGes Inc

Introduction

AnGes Inc (AnGes) is a biopharmaceutical company, which discovers and develops gene and nucleotide-based drugs and reagents for use in the functional analysis of genetic medications. The company specializes in the research and development (R&D) and practical application of genetic medicines. It has two main projects under development, namely, a hepatocyte growth factor (HGF) plasmid, which is a genetic medicine that improves blood circulation by regenerating blood vessels and NF-KB decoy oligonucleotide. It also develops therapeutic vaccine projects including CIN (cervical intraepithelial neoplasia) therapeutic vaccines. The company has operations in the US and Japan. AnGes is headquartered in Ibaraki, Osaka, Japan.

Company info

Country (HQ): Japan
Sector: Pharmaceuticals and Healthcare
Market Cap (US$ m): 152
Revenue (US$ m): 0.5 (2022)

Innovation ranking

358

Innovation score

Closest peers in the Pharmaceuticals and Healthcare sector

Innovation Ranking

Company
Headquarters
Sector

Johnson & Johnson

United States

Pharmaceuticals and Healthcare

F. Hoffmann-La Roche Ltd

Switzerland

Pharmaceuticals and Healthcare

AnGes Inc

Japan

Pharmaceuticals and Healthcare

EyeGate Pharmaceuticals Inc

United States

Pharmaceuticals and Healthcare

Shin Poong Pharm Co Ltd

South Korea

Pharmaceuticals and Healthcare

Are you ranked? Get the Innovation Ranking Report

  • Company Ranking Report
    • If your company is ranked you can get more detailed information about your ranking through the Innovation Ranking Report
    • Full company scorecard across the 3 pillars and 19 data indicators that make up the ranking score
    • Contextualised information on the company's standing in relation to peers
    • Key takeaways on the company's position in its sector, country and its standing in relation to key industry themes
    • Tips on how to use your ranking to tell a unique and compelling story in your marketing, benchmarking and hiring processes
  • Rosettes
  • Certificate of Achievement
  • Press release
Screenshot of Deal Makers